Denali Advisors LLC Invests $209,000 in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Denali Advisors LLC purchased a new position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 6,200 shares of the biotechnology company’s stock, valued at approximately $209,000.

Other institutional investors also recently made changes to their positions in the company. AJOVista LLC purchased a new stake in shares of Arcturus Therapeutics during the fourth quarter valued at $65,000. Quest Partners LLC bought a new stake in shares of Arcturus Therapeutics during the fourth quarter valued at approximately $67,000. Public Employees Retirement System of Ohio acquired a new stake in Arcturus Therapeutics in the 4th quarter valued at $89,000. China Universal Asset Management Co. Ltd. boosted its stake in Arcturus Therapeutics by 352.3% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 3,089 shares of the biotechnology company’s stock worth $97,000 after purchasing an additional 2,406 shares in the last quarter. Finally, Arizona State Retirement System bought a new stake in Arcturus Therapeutics in the fourth quarter valued at about $211,000. 94.54% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Stock Performance

Shares of ARCT traded up $0.45 during midday trading on Wednesday, hitting $21.93. 495,421 shares of the company traded hands, compared to its average volume of 526,050. The firm has a 50 day moving average of $29.99 and a 200-day moving average of $32.57. Arcturus Therapeutics Holdings Inc. has a 52 week low of $17.52 and a 52 week high of $45.00. The stock has a market cap of $590.57 million, a price-to-earnings ratio of -5.49 and a beta of 2.65.

Arcturus Therapeutics (NASDAQ:ARCT) last released its quarterly earnings data on Wednesday, May 8th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.17) by $0.17. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. The firm had revenue of $38.01 million for the quarter, compared to the consensus estimate of $22.12 million. Sell-side analysts predict that Arcturus Therapeutics Holdings Inc. will post -4.39 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ARCT has been the subject of several recent research reports. Canaccord Genuity Group reduced their price target on Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating for the company in a research report on Friday, May 10th. William Blair restated an “outperform” rating on shares of Arcturus Therapeutics in a research note on Thursday, May 23rd. Finally, HC Wainwright reissued a “buy” rating and set a $60.00 price objective on shares of Arcturus Therapeutics in a report on Tuesday. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $64.86.

Insiders Place Their Bets

In related news, COO Pad Chivukula sold 26,000 shares of the stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $40.01, for a total transaction of $1,040,260.00. Following the completion of the sale, the chief operating officer now owns 447,448 shares in the company, valued at approximately $17,902,394.48. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 13.80% of the stock is owned by insiders.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.